Scynexis Financials
| SCYX Stock | USD 1.19 0.01 0.85% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.78 | 6.2636 |
|
|
The essential information of the day-to-day investment outlook for Scynexis includes many different criteria found on its balance sheet. An individual investor should monitor Scynexis' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Scynexis.
Net Income |
|
Scynexis | Select Account or Indicator |
Understanding current and past Scynexis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Scynexis' financial statements are interrelated, with each one affecting the others. For example, an increase in Scynexis' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Scynexis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Scynexis. Check Scynexis' Beneish M Score to see the likelihood of Scynexis' management manipulating its earnings.
Scynexis Stock Summary
Scynexis competes with Biofrontera, Shuttle Pharmaceuticals, Akanda Corp, China Pharma, and Phibro Animal. SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Scynexis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US8112922005 |
| CUSIP | 811292200 811292101 |
| Location | New Jersey; U.S.A |
| Business Address | 1 Evertrust Plaza, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.scynexis.com |
| Phone | 201 884 5485 |
| Currency | USD - US Dollar |
Scynexis Key Financial Ratios
| Return On Equity | -0.48 | ||||
| Operating Margin | (15.64) % | ||||
| Price To Sales | 5.23 X | ||||
| Revenue | 140.14 M | ||||
| Gross Profit | 12.85 M |
Scynexis Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 57.2M | 102.5M | 119.8M | 87.8M | 128.4M | 70.4M | |
| Other Current Liab | 3.8M | 21.7M | 5.6M | 11.4M | 7.3M | 6.0M | |
| Other Liab | 986K | 21.6M | 33.6M | 21.4M | 24.6M | 25.8M | |
| Net Debt | (27.0M) | (73.2M) | (60.9M) | 2.8M | (19.0M) | (19.9M) | |
| Retained Earnings | (271.4M) | (326.6M) | (359.5M) | (422.3M) | (355.2M) | (373.0M) | |
| Accounts Payable | 7.2M | 4.6M | 7.8M | 5.9M | 7.1M | 4.3M | |
| Cash | 41.9M | 93.0M | 104.5M | 45.8M | 34.1M | 42.3M | |
| Other Assets | 1.2M | 1.2M | 4.0M | 7.7M | 8.8M | 9.2M | |
| Long Term Debt | 11.5M | 16.5M | 28.7M | 45.4M | 12.2M | 16.9M | |
| Inventory | 725K | 520K | 1.9M | 463K | 899K | 0.0 | |
| Other Current Assets | 674K | 2.3M | 3.6M | 2.6M | 5.9M | 6.2M | |
| Total Liab | 44.3M | 79.8M | 78.6M | 84.6M | 55.5M | 44.0M | |
| Total Current Assets | 52.4M | 98.2M | 109.4M | 79.1M | 102.1M | 63.5M | |
| Common Stock | 97K | 20K | 32K | 36K | 40K | 35K | |
| Net Tangible Assets | 31.2M | 12.9M | 22.8M | 40.2M | 36.2M | 23.9M | |
| Capital Surpluse | 248.9M | 284.2M | 349.4M | 400.7M | 460.8M | 284.3M | |
| Long Term Debt Total | 10.3M | 15.1M | 11.5M | 28.7M | 33.1M | 17.6M |
Scynexis Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 986K | 1.2M | 2.7M | 5.2M | 3.1M | 2.0M | |
| Total Revenue | 121K | 12.1M | 13.2M | 5.1M | 140.1M | 147.1M | |
| Gross Profit | 121K | (303K) | 12.9M | 4.5M | 124.5M | 130.7M | |
| Operating Income | (48.9M) | (51.1M) | (60.8M) | (85.8M) | 72.7M | 76.3M | |
| Ebit | (48.9M) | (51.5M) | (32.0M) | (60.7M) | 72.7M | 76.3M | |
| Research Development | 38.4M | 36.5M | 23.8M | 27.3M | 30.9M | 23.4M | |
| Ebitda | (48.6M) | (51.1M) | (31.4M) | (59.9M) | 73.5M | 77.2M | |
| Income Before Tax | (53.7M) | (58.3M) | (36.0M) | (67.5M) | 67.2M | 70.5M | |
| Net Income | (55.2M) | (55.2M) | (32.9M) | (62.8M) | 67.0M | 70.4M | |
| Income Tax Expense | 1.5M | (3.1M) | (3.1M) | (4.7M) | 138K | 144.9K | |
| Interest Income | 805K | 189K | 24K | 1.4M | 3.3M | 3.4M | |
| Tax Provision | (3.1M) | (3.1M) | (3.1M) | (4.7M) | 138K | 144.9K | |
| Net Interest Income | (1.4M) | (2.2M) | (3.9M) | (5.4M) | (4.2M) | (4.0M) |
Scynexis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scynexis's current stock value. Our valuation model uses many indicators to compare Scynexis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scynexis competition to find correlations between indicators driving Scynexis's intrinsic value. More Info.Scynexis is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Scynexis' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Scynexis' earnings, one of the primary drivers of an investment's value.Scynexis Systematic Risk
Scynexis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Scynexis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Scynexis correlated with the market. If Beta is less than 0 Scynexis generally moves in the opposite direction as compared to the market. If Scynexis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Scynexis is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Scynexis is generally in the same direction as the market. If Beta > 1 Scynexis moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Scynexis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Scynexis' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Scynexis growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Scynexis November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Scynexis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Scynexis. We use our internally-developed statistical techniques to arrive at the intrinsic value of Scynexis based on widely used predictive technical indicators. In general, we focus on analyzing Scynexis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Scynexis's daily price indicators and compare them against related drivers.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 16.77 | |||
| Value At Risk | (5.42) | |||
| Potential Upside | 5.51 |
Additional Tools for Scynexis Stock Analysis
When running Scynexis' price analysis, check to measure Scynexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scynexis is operating at the current time. Most of Scynexis' value examination focuses on studying past and present price action to predict the probability of Scynexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scynexis' price. Additionally, you may evaluate how the addition of Scynexis to your portfolios can decrease your overall portfolio volatility.